Law360, New York (April 22, 2008, 12:00 AM ET) -- The U.S. Federal Trade Commission has turned to a federal court to get three executives to comply with subpoenas as part of an investigation into whether Par Pharmaceutical Companies Inc., Paddock Laboratories Inc. and others restrained trade for making or selling a generic version of AndroGel.
The FTC asked the U.S. District Court for the District of Columbia on April 16 to force the executives to give testimony for the agency’s review of Par and Paddock’s deal with Solvay Pharmaceuticals Inc. and its two subsidiaries, Unimed...
FTC Puts Heat On Executives Amid AndroGel Probe
To view the full article, take a free trial now.
